# Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD

> **NCT03335852** · PHASE1 · COMPLETED · sponsor: **Allergan** · enrollment: 11 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Abicipar pegol

## Key facts

- **NCT ID:** NCT03335852
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-28
- **Primary completion:** 2018-10-08
- **Final completion:** 2018-10-08
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2018-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03335852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03335852, "Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03335852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*